New Delhi, May 5 (IANS) Molecular profiling can safely reduce radiotherapy for women with early-stage endometrial cancer while identifying those who would benefit from more intensive treatment, according to a study that marks a significant step forward in personalised cancer treatment.
Endometrial cancer is a type of gynaecological cancer, most often affecting women after menopause.
For women with high-intermediate-risk disease, adjuvant radiotherapy — particularly vaginal brachytherapy (a form of internal radiotherapy delivered directly to the vaginal area) — is commonly used after surgery to reduce the risk of recurrence.
However, patients don’t need it equally, and some may receive more treatment than necessary, exposing them to potential side effects without added benefit.
The study showed that molecular profiling — a method that examines the genetic and biological features of a tumour can guide clinical decisions. It helps identify which patients are most likely to benefit from radiotherapy, and which can safely avoid it.
The team enrolled 592 women across eight European countries with (high-) intermediate-risk endometrial cancer.
The results, presented at the ongoing ESTRO 2025, the annual congress of the European Society for Radiotherapy and Oncology (ESTRO) in Vienna, Austria, highlights that molecular profiling helps tailor radiotherapy decisions based on individual tumour characteristics.
Nearly half of the patients in the trial safely avoided radiation without compromising cancer control.
“By using molecular profiling, we can tailor treatment to each patient’s individual risk,” said Dr. Anne Sophie V.M. van den Heerik, lead investigator from The Leiden University Medical Center, The Netherlands.
“This approach allows us to safely reduce radiotherapy for many women while ensuring that those who need it receive the most effective therapy. It’s a major step towards more personalized and less invasive cancer treatment,” Heerik said.
Further, patients with an unfavourable molecular profile received a more intensive radiation approach, pelvic radiotherapy, instead of vaginal brachytherapy. The results suggest better locoregional control, with a recurrence rate of 8.4 per cent compared to 30.5 per cent in those who received standard treatment without molecular profiling.
The findings demonstrate that nearly half of patients can be safely spared radiotherapy while maintaining excellent survival rates.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
